Investment Thesis
Lineage Cell Therapeutics is a pre-revenue biotech company burning $8.1M annually with only $1.7M in revenue and $35.9M in cash, providing approximately 4.4 years of operational runway at current burn rates. While the balance sheet is debt-free with strong liquidity, the company lacks profitable operations and positive free cash flow, with fundamentals dependent entirely on successful clinical development and commercialization of its pipeline.
Strengths
- Strong cash position of $35.9M with zero long-term debt provides operational runway and financial flexibility
- Healthy balance sheet with positive equity of $53.9M and excellent liquidity ratios (6.89x current ratio)
- Operates in high-value cell therapeutics sector with potential for transformative treatments if successful
Risks
- Negative free cash flow of -$8.1M annually with minimal revenue generation indicates company is pre-commercialization stage with significant execution risk
- Severe operating losses (-$7.6M) and negative profitability metrics (Operating Margin: -440.2%, Net Margin: -279.0%) show no path to profitability from current operations
- Cash burn rate requires capital raises (triggering significant shareholder dilution) or clinical success within 4+ years; no revenue growth trajectory visible
Key Metrics to Watch
- Operating cash flow trend and burn rate deceleration
- Clinical trial progress milestones and regulatory approvals
- Revenue growth from any commercialized products and pathway to profitability
Financial Metrics
Revenue
1.7M
Net Income
-4.8M
EPS (Diluted)
$-0.03
Free Cash Flow
-8.1M
Total Assets
109.5M
Cash
35.9M
Profitability Ratios
Gross Margin
479.7%
Operating Margin
-440.2%
Net Margin
-279.0%
ROE
-8.9%
ROA
-4.4%
FCF Margin
-471.5%
Balance Sheet & Liquidity
Current Ratio
6.89x
Quick Ratio
6.89x
Debt/Equity
0.00x
Debt/Assets
51.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:44:47.117735 |
Data as of: 2026-03-31 |
Powered by Claude AI